Abstract
Purpose.:
To examine the relationship between retinal vascular geometric parameters with retinal nerve fiber layer (RNFL) and ganglion cell-inner plexiform layer (GC-IPL) parameters in nonglaucomatous subjects.
Methods.:
Study subjects were identified from the Singapore Chinese Eye Study (SCES), a population-based survey of Singaporean Chinese aged 40 to 80 years. All subjects underwent standardized systemic and ocular examinations. Nonglaucomatous eyes were defined as eyes with normal, reliable visual field results. Retinal vascular parameters (retinal vascular fractal dimension, tortuosity, and caliber) were measured from retinal photographs by using a computer-assisted program, according to a standardized protocol. Spectral-domain optical coherence tomography (SD-OCT) was used to measure RNFL and macular GC-IPL thicknesses.
Results.:
A total of 352 nonglaucomatous subjects with gradable retinal photographs and OCT images were included for the final analyses. In multiple regression analyses, after adjusting for age, sex, hypertension, diabetes, axial length, disc area, and OCT signal strength; decreased retinal vascular fractal dimension (β = −1.60, P = 0.002), narrower retinal arteriolar caliber (β = −1.60, P = 0.001), and venular caliber (β = −1.97, P < 0.001) were independently associated with thinner average RNFL thickness. In addition, decreased retinal vascular fractal dimension (β = −0.77, P = 0.017) and decreased retinal venular tortuosity (β = −0.63, P = 0.042) were independently associated with thinner average GC-IPL thickness after adjusting for age, sex, hypertension, diabetes, axial length, and OCT signal strength.
Conclusions.:
Rarefaction, vasoconstriction, and straightening of the retinal vasculature are associated with thinner RNFL and GC-IPL thickness. This information may potentially provide further insights on the role of vascular processes in glaucoma development and progression.
Standardized visual field testing was performed with static automated perimetry (Swedish Interactive Threshold Algorithm standard 24-2, Humphrey Field Analyzer II; Carl Zeiss Meditec, Dublin, CA). A visual field was defined as reliable when fixation losses were less than 20%, and false-positive, false-negative rates were less than 33%. A glaucomatous visual field defect was defined as the presence of three or more significant (P < 0.05) nonedge contiguous points with at least one at the P < 0.01 level on the same side of the horizontal meridian in the pattern deviation plot, and classified as “outside normal limits” on the Glaucoma Hemifield Test, confirmed on two consecutive visual field examinations. All subjects included for the final analysis had reliable, normal visual field.
Systolic and diastolic blood pressures were measured using a digital automatic blood pressure monitor (Dinamap model Pro Series DP110X-RW, 100V2; GE Medical Systems Information Technologies, Inc., Milwaukee, WI), after subjects were seated for at least 5 minutes. Two measurements were obtained, 5 minutes apart. A third measurement was made if the systolic pressure readings differed by more than 10 mm Hg or the diastolic pressure readings by 5 mm Hg. The mean of the two closest readings was then recorded as the subject's blood pressure. Hypertension was defined as systolic blood pressure of ≥140 mm Hg or diastolic pressure of ≥90 mm Hg at the time of the examination, or a reported history of physician-diagnosed hypertension or self-reported history of antihypertensive medication use, or both.
Nonfasting venous blood samples were analyzed at the National University Hospital Reference Laboratory for biochemical testing of glycosylated hemoglobin (HbA1c) and serum glucose level. Diabetes mellitus was defined as nonfasting glucose ≥11.1 mmol/L or subjects' self-reported use of diabetic medication or a reported history of physician-diagnosed diabetes.
Supported by grants from the National Medical Research Council and the Biomedical Research Council, Singapore.
Disclosure: Y.-C. Tham; None; C.-Y. Cheng; None; Y. Zheng, None; T. Aung, Carl Zeiss Meditec (F, R); T.Y. Wong, None; C.Y. Cheung, None